Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellMEX:OMCL 75 EV-to-EBITDA is 10.26 as of Aug. 01, 2026, which is 64% below its 10-year median of 28.65. GuruFocus rates MEX:OMCL with a GF Score™ of 75/100 and a GF Value™ of MXN831.75. The stock has 6 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Omnicell ranks worse than 58.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Omnicell's enterprise value is MXN26,110 Mil.
Omnicell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MXN2,545 Mil. Therefore, Omnicell's EV-to-EBITDA for today is 10.26.
The historical rank and industry rank for Omnicell's EV-to-EBITDA or its related term are showing as below:
MEX:OMCL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.57 Med: 28.65 Max: 58.55
Current: 10.57
During the past 13 years, the highest EV-to-EBITDA of Omnicell was 58.55. The lowest was 10.57. And the median was 28.65.
MEX:OMCL's EV-to-EBITDA is ranked worse than 58.35% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.04
vs MEX:OMCL: 10.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Omnicell's share price for today is MXN761.16.
Omnicell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN14.793.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Omnicell's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OMCL vs HTFL, TDOC, OMDA: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Omnicell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Omnicell's EV-to-EBITDA falls into.
Omnicell's current Enterprise Value is MXN26,110 Mil.
Omnicell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,545 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (MEX:OMCL) has a EV-to-EBITDA of 10.26 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Omnicell. This is 64% below median its historical median of 28.65. Over the past decade, Omnicell's EV-to-EBITDA has ranged from 10.57 to 58.55. According to the industry distribution chart, Omnicell ranks #297 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 58.3%.
Is Omnicell's EV-to-EBITDA too high?
Omnicell's current EV-to-EBITDA of 10.26 is 64% below median its 10-year median of 28.65. Over the past 10 years, this metric has ranged from a low of 10.57 to a high of 58.55. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.04. Omnicell's value of 10.26 is 7.1% below this industry median. Based on the distribution chart, Omnicell ranks #297 out of 509 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Omnicell has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's EV-to-EBITDA compare to HTFL and TDOC?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #297 out of 509 companies for EV-to-EBITDA. This places Omnicell in the lower half of its industry. The industry median EV-to-EBITDA is 11.04. Omnicell's value of 10.26 is 7.1% below this benchmark. Historically, Omnicell's own EV-to-EBITDA has ranged from 10.57 to 58.55 over the past decade. While the company's 10-year median is 28.65 vs. the industry median of 11.04, Omnicell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.04, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current EV-to-EBITDA of 10.26 is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Omnicell. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current EV-to-EBITDA is 10.26, which is 64% below median its own 10-year median of 28.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (MEX:OMCL) has a current EV-to-EBITDA of 10.26. The stock's GF Value™ is MXN831.75, compared to a current price of MXN761.16 — trading 8.5% below its estimated fair value. The current EV-to-EBITDA is 10.26, which is 64% below median its 10-year median of 28.65 and 7.1% below the Healthcare Providers & Services industry median of 11.04. Omnicell's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current EV-to-EBITDA is 10.26 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be undervalued.
The current stock price of MXN761.16 is trading 8.5% below its estimated GF Value™ of MXN831.75.
Key valuation signals for MEX:OMCL:
EV-to-EBITDA: 10.26 (64% below median its 10-year median of 28.65)
GF Value™: MXN831.75 vs. price of MXN761.16 (8.5% below fair value)
Industry Position: 7.1% below the Healthcare Providers & Services median (#297 of 509)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
75GF Score
Get the complete analysis for MEX:OMCL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
